Payment overview · 2025
General Payments
$227.70
11 reported records · 6 companies
Healthcare provider profile · identity verified
Thai Ly, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TACOMA, WA · NPI 1346902509
Verified facts
What the public records show
CMS Open Payments records show Thai Ly, ARNP received $227.70 in general payments during 2025 across 11 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $69.17 | 30.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.86 | 25.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.03 | 18.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $21.97 | 9.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.56 | 8.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $15.11 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.70 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $69.17 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.86 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 570 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 434 | 85 |
| Trazodone Hcl | Trazodone Hcl | 406 | 68 |
| Gabapentin | Gabapentin | 360 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 52 |
| Lisinopril | Lisinopril | 245 | 47 |
| Mirtazapine | Mirtazapine | 227 | 34 |
| Furosemide | Furosemide | 226 | 47 |
| Donepezil Hcl | Donepezil Hcl | 209 | 34 |
| Potassium Chloride | Potassium Chloride | 206 | 37 |
| Sertraline Hcl | Sertraline Hcl | 205 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 37 |
| Losartan Potassium | Losartan Potassium | 177 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 27 |
| Omeprazole | Omeprazole | 152 | 31 |
| Buspirone Hcl | Buspirone Hcl | 150 | 27 |
| Metformin Hcl | Metformin Hcl | 150 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 28 |
| Risperidone | Risperidone | 127 | 20 |
| Eliquis | Apixaban | 122 | 26 |
| Famotidine | Famotidine | 122 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 24 |
| Lorazepam | Lorazepam | 116 | 48 |
| Simvastatin | Simvastatin | 111 | 15 |
| Olanzapine | Olanzapine | 108 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 20 |
| Memantine Hcl | Memantine Hcl | 106 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 96 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 17 |
| Tramadol Hcl | Tramadol Hcl | 91 | 28 |
| Divalproex Sodium | Divalproex Sodium | 90 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 17 |
| Torsemide | Torsemide | 77 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 11 |
| Spironolactone | Spironolactone | 67 | 18 |
| Carvedilol | Carvedilol | 65 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 13 |
| Xarelto | Rivaroxaban | 62 | 12 |
| Meloxicam | Meloxicam | 60 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 20 |
| Finasteride | Finasteride | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 22 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 30 |
| Loperamide | Loperamide Hcl | 47 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 15 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 41 | 21 |
| Baclofen | Baclofen | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Nystatin | Nystatin | 32 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 20 |
| Haloperidol | Haloperidol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Ciclopirox | Ciclopirox | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Alprazolam | Alprazolam | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.70 · 11 records | Teva Pharmaceuticals USA, Inc. | ARISTADA, AUSTEDO XR, Arikayce, Brinsupri, CAPLYTA, LYBALVI, Ozempic, REXULTI, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error